KRAS and cancer: Indeed, abundant research underscores the substantial impact of the PI3K/AKT pathway on the response of KRAS-mutant cancer to MEK inhibition [30, 31] and the efficacy of concurrently targeting both the MAPK and PI3K/AKT signaling pathways has been demonstrated [32, 33].